Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
29
1
2019
Statut:
ppublish
Résumé
At present, there is no uniform consensus on the treatment of recurrent glioblastoma, especially the re-irradiation dose and temozolomide (TMZ) dose. The literature on the treatment of recurrent glioblastoma (GBM) by conventionally fractionated stereotactic radiotherapy (CFRT) is even rarer. A 44-year-old woman was admitted to our hospital for residual tumor after reoperation. Postoperative pathological diagnosis was GBM, WHO grade IV. The brain magnetic resonance imaging re-examination showed abnormal enhancement around the local operative region after resection of the left frontal lobe tumor, and there was presence of residual tumor. The patient was treated with reoperation followed by re-irradiation plus dose-dense TMZ to achieve complete remission. Complete remission was observed at the end of radiotherapy and at the 1 month follow-up after radiotherapy. This study suggests that CFRT plus dose-dense TMZ might be a feasible option for the treatment in relapsed malignant glioma patients with good general condition.
Identifiants
pubmed: 30608405
doi: 10.1097/MD.0000000000013869
pii: 00005792-201901040-00025
pmc: PMC6344191
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Temozolomide
YF1K15M17Y
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13869Références
World Neurosurg. 2012 Dec;78(6):658-69
pubmed: 22484078
Neurosurgery. 2005 Oct;57(4):684-92; discussion 684-92
pubmed: 16239880
Clin Neurol Neurosurg. 2011 Jul;113(6):509-12
pubmed: 21392883
Cancer. 2005 Nov 15;104(10):2168-73
pubmed: 16220556
J Neurooncol. 2007 Feb;81(3):287-94
pubmed: 17031558
J Clin Oncol. 2010 Jun 20;28(18):3048-53
pubmed: 20479391
Am J Clin Oncol. 2013 Jun;36(3):261-8
pubmed: 22495452
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):107-12
pubmed: 22019245
Acta Oncol. 2013 Jan;52(1):147-52
pubmed: 22686472
Radiother Oncol. 2011 Jan;98(1):1-14
pubmed: 21159396
Biomed Res Int. 2014;2014:657953
pubmed: 24895599
J Neurooncol. 2009 Apr;92(2):185-91
pubmed: 19066727
Ann Transl Med. 2014 May;2(5):44
pubmed: 25333019
Cancer Med. 2013 Dec;2(6):942-9
pubmed: 24403268
J Clin Oncol. 2005 Dec 1;23(34):8863-9
pubmed: 16314646
BMC Cancer. 2005 May 30;5:55
pubmed: 15924621
Crit Rev Oncol Hematol. 2018 Jun;126:80-91
pubmed: 29759570
Acta Neurochir (Wien). 2012 Feb;154(2):203-9
pubmed: 21984132
J Neurooncol. 2013 Jul;113(3):403-9
pubmed: 23589034
Yonsei Med J. 2016 Jul;57(4):824-30
pubmed: 27189273
Cancer. 2008 May 1;112(9):2046-51
pubmed: 18338759